• 1. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 5. Evolved polymerases facilitate selection of fully 2′-OMe-modified aptamers?
  Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182

Introduction to 4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-amine (CAS No. 50825-19-9)

4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-amine, identified by the Chemical Abstracts Service Number (CAS No.) 50825-19-9, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This compound belongs to the thiazole and indole chemical classes, which are well-documented for their diverse biological activities and potential therapeutic applications. The structural motif of this molecule combines a thiazole ring with an indole moiety, creating a framework that is conducive to interactions with biological targets, particularly enzymes and receptors involved in critical metabolic pathways.

The indole component of 4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-amine is a well-known pharmacophore in drug discovery, known for its presence in numerous bioactive natural products and synthetic drugs. Indole derivatives have been extensively studied for their roles in modulating neurological functions, immune responses, and cancer cell proliferation. In contrast, the thiazole ring is another pharmacologically relevant scaffold, widely recognized for its antimicrobial, antifungal, anti-inflammatory, and cardiovascular effects. The combination of these two heterocyclic systems in 4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-amine suggests a potential for multifunctional activity, which has spurred interest in its pharmacological evaluation.

Recent advancements in computational chemistry and high-throughput screening have facilitated the rapid identification of novel bioactive compounds like 4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-amine. The structural features of this compound make it a promising candidate for further investigation as an intermediate in the synthesis of more complex pharmaceutical agents. Specifically, the presence of a methyl group at the 2-position of the indole ring and an amine substituent on the thiazole ring provides multiple sites for functionalization, allowing chemists to tailor its properties for specific biological targets.

In the context of modern drug development, there is a growing emphasis on identifying compounds that exhibit dual or polypharmacological activity. This approach aims to address complex diseases by targeting multiple pathways simultaneously, thereby improving therapeutic efficacy and reducing side effects. The structural design of 4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-amine aligns with this trend, as its combined indole-thiazole framework could potentially interact with several key biological targets. For instance, studies have suggested that indole derivatives may modulate neurotransmitter systems, while thiazole compounds can influence enzyme activities related to inflammation and metabolism.

The synthesis of 4-(2-methyl-1H-indol-3-yl)-1,3-thiazol-2-am ine involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Key synthetic steps typically include condensation reactions between appropriate precursors followed by functional group transformations such as cyclization and amination. Advances in synthetic methodologies have enabled more efficient and scalable production processes for such heterocyclic compounds. For example, transition-metal-catalyzed cross-coupling reactions have been employed to construct the carbon-carbon bonds within the indole and thiazole moieties with high precision.

From a biological perspective, 4-(2-methyl -1H-ind ol -3 -y l)- 1 , 3 -th i az ol - 2 -am ine has been investigated for its potential role in modulating inflammatory pathways. Inflammatory processes are central to numerous chronic diseases, including arthritis, cardiovascular disorders, and certain types of cancer. Preclinical studies have demonstrated that compounds with structural similarities to 4-(2-methyl -1H-ind ol -3 -y l)- 1 , 3 -th i az ol - 2 -am ine can inhibit key pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα) and interleukin-beta (ILβ). These findings suggest that this compound may serve as a lead structure for developing novel anti-inflammatory agents.

In addition to its anti-inflammatory potential,4-( 2 -m ethyl - 1 H-ind ol - 3 -y l ) - 1 , 3 -th i az ol - 2 -am ine has shown promise in preclinical models related to neurodegenerative diseases. The indole moiety is particularly relevant here due to its known interactions with serotonin receptors (5-HT receptors), which play a crucial role in regulating mood and cognitive function. Dysregulation of these pathways has been implicated in conditions such as Alzheimer's disease and Parkinson's disease. Early studies indicate that derivatives of this compound may help mitigate neuroinflammation and protect against neuronal damage caused by oxidative stress.

The pharmacokinetic properties of 4-( 2 -m ethyl - 1 H-ind ol - 3 -y l ) - 1 , 3 -th i az ol - 2 -am ine are also under investigation to assess its suitability as a drug candidate. Factors such as solubility, stability in biological fluids, metabolic clearance rates, and potential for drug-drug interactions are critical considerations during early-stage development. Computational modeling techniques have been employed to predict how this compound might behave within the human body based on its molecular structure. These simulations help identify potential liabilities early in the discovery process before costly experimental trials are conducted.

Future research directions for 4-( 2 m ethyl-l H-in dol--33 y l )--13 t h i az o l --22 am ine include exploring its mechanism of action at a molecular level through structural biology techniques such as X-ray crystallography or cryo-electron microscopy (cryoEM). Understanding how this compound interacts with target proteins or enzymes will provide valuable insights into its biological effects and guide further optimization efforts toward improving potency while minimizing off-target effects.

The integration of artificial intelligence (AI) into drug discovery workflows has accelerated the identification of promising candidates like 4-(methyl-l H-indol--33 y l)--13-thiazol--22-am ine). Machine learning algorithms can analyze vast datasets containing chemical structures alongside their biological activities to predict new leads efficiently. By leveraging these technologies, researchers aim not only to discover new therapeutic agents but also to design molecules with improved pharmacokinetic profiles tailored specifically for oral administration or targeted delivery systems.

In conclusion,4-(m ethyl-l H-in dol--33 y l)--13-t h i az o l --22 am ine (CAS No .50825--19--9) represents an exciting opportunity within pharmaceutical research due lo its unique structural features combined w ith preliminary evidence o f bioactivity . As investigations continue into both synthetic methods n d pharmacological effects,this compound holds promise f or contributing lo next-generation treatments across multiple therapeutic areas . Its study exemplifies how interdisciplinary approaches merging organic chemistry,* computational biology,* n d medicinal biology* can drive innovation n modern drug development .

• 793727-92-1(4-(1,2,5-trimethyl-1H-pyrrol-3-yl)-1,3-thiazol-2-amine)
• 22258-56-6(4-(1H-indol-3-yl)-1,3-thiazol-2-amine)
• 875638-27-0(2-Thiazolamine, 4-[5-(1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-)
• 488816-76-8(4-(quinolin-3-yl)-1,3-thiazol-2-amine)
• 843622-17-3(4-(1,2-Dimethyl-1H-indol-3-yl)-1,3-thiazol-2-amine)
• 893729-86-7(4-(5-Fluoro-1H-indol-3-yl)-1,3-thiazol-2-amine)
• 50825-20-2(4-(5-Methoxy-2-methyl-1H-indol-3-yl)thiazol-2-amine)
• 189011-04-9(4-(1-methyl-1H-indol-3-yl)-1,3-thiazol-2-amine)
• 1170999-18-4(4-(1,2,5-trimethyl-1H-pyrrol-3-yl)-1,3-thiazol-2-amine hydrochloride)
• 382622-81-3(4-(2,6-Dimethyl-1H-indol-3-yl)-1,3-thiazol-2-amine)